Johannes Bruno Mueller-Reif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johannes Bruno Mueller-Reif has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
- Matthias Mann
Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
25 shared publications - Philipp Emanuel Geyer
Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany
15 shared publications - Vincent Albrecht
Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
9 shared publications - Kathrin Korff
Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
7 shared publications - Daniel Teupser
Institute of Laboratory Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany
5 shared publications Alicia-Sophie Schebesta
Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
4 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in Molecular & Cellular Proteomics
In situ polymerized monolith tips for reproducible, format-flexible proteomic sample preparation applied to biofluids
- 27 October 2026
- Published by Elsevier in Molecular & Cellular Proteomics
Open AccessIn situ polymerized monolith tips for reproducible, format-flexible proteomic sample preparation applied to biofluids
- Open Access
FastaLake selects compact metaproteomic databases from large sequence reservoirs by de novo peptide lookup
Metaproteomics analyses require protein sequence databases, yet the microbial proteins present in complex communities are not known in advance. Searching reference catalogs containing hundreds of millions of candidate sequences reduces identification sensitivity, while generating sample-specific databases through metagenomic sequencing adds time and cost. We introduce FastaLake, a computational workflow that uses full-length de novo peptide predictions by AlphaNovo to retrieve complete proteins from broad sequence resources and selects compact databases for conventional searching. In a defined eight-member community, FastaLake approached reference-search peptide yields without knowing its members. Using public sequence catalogs, FastaLake identified about as many peptides as matched metagenomic databases in two stool cohorts and 20–35% more in intestinal fluid at the same nominal 1% peptide false discovery rate. The resulting proteomes reveal personal functional profiles that persist across intestinal regions despite differences in leading species between intestinal fluid and stool. DNA, RNA and protein profiles agreed on broad differences between patients but only weakly on individual functions. All 726 acquisition-specific databases were smaller than the human reference proteome. Compact databases allowed non-specific searches of all 347 CapScan acquisitions, revealing histidine enrichment at peptide C termini in intestinal fluid. FastaLake enables metaproteomics analysis without matched metagenomic sequencing by constructing search databases from sequence resources and de novo peptide sequencing.
Open AccessFastaLake selects compact metaproteomic databases from large sequence reservoirs by de novo peptide lookup
Metaproteomics analyses require protein sequence databases, yet the microbial proteins present in complex communities are not known in advance. Searching reference catalogs containing hundreds of millions of candidate sequences reduces identification sensitivity, while generating sample-specific databases through metagenomic sequencing adds time and cost. We introduce FastaLake, a computational workflow that uses full-length de novo peptide predictions by AlphaNovo to retrieve complete proteins from broad sequence resources and selects compact databases for conventional searching. In a defined eight-member community, FastaLake approached reference-search peptide yields without knowing its members. Using public sequence catalogs, FastaLake identified about as many peptides as matched metagenomic databases in two stool cohorts and 20–35% more in intestinal fluid at the same nominal 1% peptide false discovery rate. The resulting proteomes reveal personal functional profiles that persist across intestinal regions despite differences in leading species between intestinal fluid and stool. DNA, RNA and protein profiles agreed on broad differences between patients but only weakly on individual functions. All 726 acquisition-specific databases were smaller than the human reference proteome. Compact databases allowed non-specific searches of all 347 CapScan acquisitions, revealing histidine enrichment at peptide C termini in intestinal fluid. FastaLake enables metaproteomics analysis without matched metagenomic sequencing by constructing search databases from sequence resources and de novo peptide sequencing.
- Open Access
Differentiating benign from malignant adnexal masses by biomarker-agnostic plasma proteomics using adaptive machine learning
Summary: Background: Pre-operative triage of adnexal masses with serum CA-125, HE4, and ultrasound (O-RADS) has limited accuracy, contributing to unnecessary surgery. We develop and validate a first of its kind, biomarker panel-free plasma proteomic classifier that distinguishes malignant from benign adnexal masses from a single blood draw, operating directly on discovery-mode mass spectrometry. Methods: In this multicenter prospective observational study, plasma from women with adnexal masses and from healthy controls at a large urban academic center (discovery and four validation cohorts) and an external academic center from another Urban-suburban area (external validation) was analyzed by data-independent-acquisition mass spectrometry (Orbitrap Astral), quantifying >1,000 proteins per sample. Cancerous (malignant, borderline adnexal mass, or metastasis to ovary) versus benign adnexal masses were classified with ADAPT-MS (Adaptive Diagnostic Architecture for Personalized Testing by Mass Spectrometry), which retrains an ElasticNet model for each sample based on the proteins measured. The primary outcome was discrimination (area under the receiver operating characteristic curve [AUC]). Pre-operative O-RADS scores and serum CA-125 were compared and combined with proteomics on matched subsets. Findings: Using a discovery cohort (n=1062), an ADAPT-MS classifier, validated across five independent cohorts (n=623), achieved a summary AUC of 0.835 (cohort range 0.779–0.904). Among patients with pre-operative O-RADS (n=231), proteomics (AUC 0.852) was comparable to O-RADS alone (0.863) and combining them raised discrimination to 0.922. Proteomics outperformed serum CA-125 (0.915 versus 0.777; n=125) and proteome-derived ROMA-like and two-marker surrogates. Biologically, the classification-relevant proteins are enriched for host response proteins rather than tumor cell associated protein changes, comprising ECM remodeling, complement and innate immune response pathways. This explains good detection of tumor with heterogenous pathology and also metastasis to ovary. Interpretation: A single plasma proteomic measurement interpreted using adaptive machine learning discriminates malignant from benign adnexal masses with good internal and external validation, and is complementary to ultrasound, warranting prospective evaluation as a panel-free diagnostic adjunct to imaging. Funding: Funded by the Max Planck Society for the Advancement of Sciences (MM), an NIH R35 grant (EL), and support from Arthur and Nicole Herbst (EL). Research in context: Evidence before this study: Presence of protein biomarkers for ovarian cancer and in detail, adnexal mass triage is historically present e.g. by CA-125 or HE4. Proteomics studies have shown many more potential protein markers that might be used as biomarkers instead or additional to the presently used ones. Classification algorithms however do currently rely on single or few biomarkers only, limiting sensitivity and specificity. Added value of this study: To our knowledge, this study is the first example of a proteomics classifier that uses ML on discovery-based MS-proteomics data at the single-sample level and thus has the potential for diagnostic use. While in the past, proteomics has been used as a discovery tool and potential markers needed to be subjected to a follow-up assay development, we show by application to 5 different independent validation cohorts that a proteomics classifier based on the recently developed architecture Adaptive Diagnostic Architecture for Personalized Testing by Mass Spectrometry (ADAPT-MS) generalizes in performance between discovery and validation cohorts and can be applied at the single sample level. Implications of all the available evidence: We demonstrate that proteomics can be applied beyond discovery and classify adnexal masses together with ultrasound at an AUC of 0.922. This sets a precedence case for other diagnostic applications of proteomics, both in study design (plasma proteomics is always measured and used to best of ability in discovery and validation), and in single-sample application mode by ADAPT-MS.
Open AccessDifferentiating benign from malignant adnexal masses by biomarker-agnostic plasma proteomics using adaptive machine learning
Summary: Background: Pre-operative triage of adnexal masses with serum CA-125, HE4, and ultrasound (O-RADS) has limited accuracy, contributing to unnecessary surgery. We develop and validate a first of its kind, biomarker panel-free plasma proteomic classifier that distinguishes malignant from benign adnexal masses from a single blood draw, operating directly on discovery-mode mass spectrometry. Methods: In this multicenter prospective observational study, plasma from women with adnexal masses and from healthy controls at a large urban academic center (discovery and four validation cohorts) and an external academic center from another Urban-suburban area (external validation) was analyzed by data-independent-acquisition mass spectrometry (Orbitrap Astral), quantifying >1,000 proteins per sample. Cancerous (malignant, borderline adnexal mass, or metastasis to ovary) versus benign adnexal masses were classified with ADAPT-MS (Adaptive Diagnostic Architecture for Personalized Testing by Mass Spectrometry), which retrains an ElasticNet model for each sample based on the proteins measured. The primary outcome was discrimination (area under the receiver operating characteristic curve [AUC]). Pre-operative O-RADS scores and serum CA-125 were compared and combined with proteomics on matched subsets. Findings: Using a discovery cohort (n=1062), an ADAPT-MS classifier, validated across five independent cohorts (n=623), achieved a summary AUC of 0.835 (cohort range 0.779–0.904). Among patients with pre-operative O-RADS (n=231), proteomics (AUC 0.852) was comparable to O-RADS alone (0.863) and combining them raised discrimination to 0.922. Proteomics outperformed serum CA-125 (0.915 versus 0.777; n=125) and proteome-derived ROMA-like and two-marker surrogates. Biologically, the classification-relevant proteins are enriched for host response proteins rather than tumor cell associated protein changes, comprising ECM remodeling, complement and innate immune response pathways. This explains good detection of tumor with heterogenous pathology and also metastasis to ovary. Interpretation: A single plasma proteomic measurement interpreted using adaptive machine learning discriminates malignant from benign adnexal masses with good internal and external validation, and is complementary to ultrasound, warranting prospective evaluation as a panel-free diagnostic adjunct to imaging. Funding: Funded by the Max Planck Society for the Advancement of Sciences (MM), an NIH R35 grant (EL), and support from Arthur and Nicole Herbst (EL). Research in context: Evidence before this study: Presence of protein biomarkers for ovarian cancer and in detail, adnexal mass triage is historically present e.g. by CA-125 or HE4. Proteomics studies have shown many more potential protein markers that might be used as biomarkers instead or additional to the presently used ones. Classification algorithms however do currently rely on single or few biomarkers only, limiting sensitivity and specificity. Added value of this study: To our knowledge, this study is the first example of a proteomics classifier that uses ML on discovery-based MS-proteomics data at the single-sample level and thus has the potential for diagnostic use. While in the past, proteomics has been used as a discovery tool and potential markers needed to be subjected to a follow-up assay development, we show by application to 5 different independent validation cohorts that a proteomics classifier based on the recently developed architecture Adaptive Diagnostic Architecture for Personalized Testing by Mass Spectrometry (ADAPT-MS) generalizes in performance between discovery and validation cohorts and can be applied at the single sample level. Implications of all the available evidence: We demonstrate that proteomics can be applied beyond discovery and classify adnexal masses together with ultrasound at an AUC of 0.922. This sets a precedence case for other diagnostic applications of proteomics, both in study design (plasma proteomics is always measured and used to best of ability in discovery and validation), and in single-sample application mode by ADAPT-MS.
- Open Access
- 22 June 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (7) , 101609
Limited impact of column chemistry and length on proteome coverage under high-speed DIA
- 22 June 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (7) , 101609
Open AccessLimited impact of column chemistry and length on proteome coverage under high-speed DIA
- Open Access
In situ polymerized monolith tips for reproducible, format-flexible proteomic sample preparation applied to biofluids
Sample preparation increasingly sets the throughput and reproducibility of mass spectrometry (MS)-based proteomics. StageTips (stop-and-go extraction tips) and variants thereof have long been common implements to purify samples, and we recently extended the concept to solid-phase extraction capture (SPEC) tips, in which the entire digestion takes place in sub-microliter volumes. Here we replace the hand-packed bed with a strong anion-exchange (SAX) monolith photopolymerized directly inside the pipette tip from a defined recipe (pSPEC). A liquid-handling robot casts 384 tunable tips in minutes, at low cost and in any format, adding negligibly to the workflow's variance. Across biofluids, pSPEC added ~20% more identifications than in-solution plasma and reached 3,500 protein groups from a single injection of healthy urine and 4,800 from saliva at 100 samples per day, depths usually requiring depletion or fractionation. The same light-cast chemistry should extend to single cells, affinity capture, and population-scale studies.
Open AccessIn situ polymerized monolith tips for reproducible, format-flexible proteomic sample preparation applied to biofluids
Sample preparation increasingly sets the throughput and reproducibility of mass spectrometry (MS)-based proteomics. StageTips (stop-and-go extraction tips) and variants thereof have long been common implements to purify samples, and we recently extended the concept to solid-phase extraction capture (SPEC) tips, in which the entire digestion takes place in sub-microliter volumes. Here we replace the hand-packed bed with a strong anion-exchange (SAX) monolith photopolymerized directly inside the pipette tip from a defined recipe (pSPEC). A liquid-handling robot casts 384 tunable tips in minutes, at low cost and in any format, adding negligibly to the workflow's variance. Across biofluids, pSPEC added ~20% more identifications than in-solution plasma and reached 3,500 protein groups from a single injection of healthy urine and 4,800 from saliva at 100 samples per day, depths usually requiring depletion or fractionation. The same light-cast chemistry should extend to single cells, affinity capture, and population-scale studies.
- Open Access
- 23 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (11)
Longitudinal clinical proteomics reveals pneumonia type–specific protein biomarkers and autoantibodies
Community-acquired pneumonia is a major cause of morbidity and mortality globally. Specific molecular endotypes are currently not well defined, and different viral or bacterial pathogens may trigger specific host responses and pathogenic mechanisms. We performed longitudinal proteomic profiling of bronchoalveolar lavage fluid and plasma from bacterial, influenza, and SARS-CoV-2–driven pneumonia. Our analysis revealed highly pneumonia type–specific proteomic signatures, including COVID-19–specific antibodies locally produced in the lung. These antibodies showed biased immunoglobulin V–domain usage, linked to a CD69 / CD83 plasma cell state associated with disease severity and degree of autoimmunity. Using mass spectrometry–driven autoantibody profiling in 2 independent COVID-19 cohorts, we identified 177 putative autoantibodies targeting extracellular matrix, nuclear, and immune-related proteins. Of note, temporal changes in autoantibody profiles correlated with clinical markers of inflammation, organ dysfunction, and duration of hospitalization. These findings highlight the autoimmune aspects of COVID-19 and provide potential biomarkers and therapeutic targets to help improve patient outcomes.
- 23 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (11)
Open AccessLongitudinal clinical proteomics reveals pneumonia type–specific protein biomarkers and autoantibodies
Community-acquired pneumonia is a major cause of morbidity and mortality globally. Specific molecular endotypes are currently not well defined, and different viral or bacterial pathogens may trigger specific host responses and pathogenic mechanisms. We performed longitudinal proteomic profiling of bronchoalveolar lavage fluid and plasma from bacterial, influenza, and SARS-CoV-2–driven pneumonia. Our analysis revealed highly pneumonia type–specific proteomic signatures, including COVID-19–specific antibodies locally produced in the lung. These antibodies showed biased immunoglobulin V–domain usage, linked to a CD69 / CD83 plasma cell state associated with disease severity and degree of autoimmunity. Using mass spectrometry–driven autoantibody profiling in 2 independent COVID-19 cohorts, we identified 177 putative autoantibodies targeting extracellular matrix, nuclear, and immune-related proteins. Of note, temporal changes in autoantibody profiles correlated with clinical markers of inflammation, organ dysfunction, and duration of hospitalization. These findings highlight the autoimmune aspects of COVID-19 and provide potential biomarkers and therapeutic targets to help improve patient outcomes.
- Open Access
- 3 April 2026
- Published by International Society of Global Health in Journal of Global Health
- Vol. 16, 05002
Multi-Omics for Mothers and Infants (MOMI) Consortium: a global initiative to study adverse pregnancy outcomes
Pregnancy complications such as preeclampsia (PE) and adverse pregnancy outcomes (APOs) such as preterm birth (PTB), small for gestational age (SGA), and stillbirth (SB) pose a serious global health challenge and collectively contribute to high rates of maternal and infant mortality and morbidity. Close to 2 million stillbirths were reported in 2020 [1,2] while […]
- 3 April 2026
- Published by International Society of Global Health in Journal of Global Health
- Vol. 16, 05002
Open AccessMulti-Omics for Mothers and Infants (MOMI) Consortium: a global initiative to study adverse pregnancy outcomes
Pregnancy complications such as preeclampsia (PE) and adverse pregnancy outcomes (APOs) such as preterm birth (PTB), small for gestational age (SGA), and stillbirth (SB) pose a serious global health challenge and collectively contribute to high rates of maternal and infant mortality and morbidity. Close to 2 million stillbirths were reported in 2020 [1,2] while […]
- Open Access
- 29 January 2026
- Published by Springer Nature in Molecular Systems Biology
- Vol. 22 (5) , 712-737
Multi-cohort, cross-species urinary proteomics reveals signatures of LRRK2 dysfunction in Parkinson’s disease
Pathogenic mutations in Leucine-rich repeat kinase 2 ( LRRK2 ) are the predominant genetic cause of Parkinson’s disease (PD) and often increase kinase activity, making LRRK2 inhibitors promising treatment options. Although LRRK2 kinase inhibitors are advancing clinically, non-invasive readouts of LRRK2-linked pathway modulation remain limited. Profiling urinary proteomes from 1215 individuals across three cohorts and integrating whole-genome sequencing from >500 participants to map genotype–proteome associations, we identified 177 urinary proteins associated with pathogenic LRRK2, enriched for lysosomal/glycosphingolipid, immune, and membrane-trafficking pathways. Machine learning narrowed the features to a cohort-agnostic 30-protein panel that classified G2019S carriers with a mean ROC AUC of 0.91 across independent tests. To evaluate translation, we performed multi-organ and urinary proteomics in rat gain- and loss-of-function models (BAC- LRRK2 G2019S and Lrrk2 KO ) and after Lrrk2 inhibition (MLi-2 and PF-475), revealing tissue-specific responses—strongest in kidney—and cross-species overlap, including 24 brain proteins detectable in human urine. Rat-derived perturbations predicted LRRK2 mutation status in patients (AUC 0.75) and reversed with Lrrk2 inhibition, supporting their pharmacodynamic utility. Together, our findings establish urine as a scalable, non-invasive matrix that captures systemic and brain-relevant consequences of LRRK2 dysfunction and nominate candidate pharmacodynamic markers set to support LRRK2-directed trials.
- 29 January 2026
- Published by Springer Nature in Molecular Systems Biology
- Vol. 22 (5) , 712-737
Open AccessMulti-cohort, cross-species urinary proteomics reveals signatures of LRRK2 dysfunction in Parkinson’s disease
Pathogenic mutations in Leucine-rich repeat kinase 2 ( LRRK2 ) are the predominant genetic cause of Parkinson’s disease (PD) and often increase kinase activity, making LRRK2 inhibitors promising treatment options. Although LRRK2 kinase inhibitors are advancing clinically, non-invasive readouts of LRRK2-linked pathway modulation remain limited. Profiling urinary proteomes from 1215 individuals across three cohorts and integrating whole-genome sequencing from >500 participants to map genotype–proteome associations, we identified 177 urinary proteins associated with pathogenic LRRK2, enriched for lysosomal/glycosphingolipid, immune, and membrane-trafficking pathways. Machine learning narrowed the features to a cohort-agnostic 30-protein panel that classified G2019S carriers with a mean ROC AUC of 0.91 across independent tests. To evaluate translation, we performed multi-organ and urinary proteomics in rat gain- and loss-of-function models (BAC- LRRK2 G2019S and Lrrk2 KO ) and after Lrrk2 inhibition (MLi-2 and PF-475), revealing tissue-specific responses—strongest in kidney—and cross-species overlap, including 24 brain proteins detectable in human urine. Rat-derived perturbations predicted LRRK2 mutation status in patients (AUC 0.75) and reversed with Lrrk2 inhibition, supporting their pharmacodynamic utility. Together, our findings establish urine as a scalable, non-invasive matrix that captures systemic and brain-relevant consequences of LRRK2 dysfunction and nominate candidate pharmacodynamic markers set to support LRRK2-directed trials.
- Open Access
- 27 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
An adaptive, continuous-learning framework for clinical decision-making from proteome-wide biofluid data
Mass spectrometry (MS)-based proteomics provides deep molecular insights from patient samples, but clinical use has been limited by missing values, static biomarker panels, and the need for targeted assay development. We present a framework – Adaptive Diagnostic Architecture for Personalized Testing by Mass Spectrometry (ADAPT-MS) – that enables direct diagnostic and prognostic interpretation of discovery-mode proteomics data at the level of individual samples. ADAPT-MS dynamically retrains simple, robust classifiers based on the proteins quantified in each sample, eliminating the need for imputation or fixed panels. Applied to plasma and cerebrospinal fluid datasets across diseases and clinical centers, it achieves high performance and generalizability using robust, transparent and generalizable statistical models. A single proteomic measurement can support multiple diagnostic questions via retrospective cohort matching, with each classification taking only seconds. As population-scale proteomics datasets grow, this approach lays the foundation for scalable, real-time, and personalized diagnostics directly from proteome-wide data. Such a community effort may help to transform discovery proteomics into a routine clinical tool.
- 27 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAn adaptive, continuous-learning framework for clinical decision-making from proteome-wide biofluid data
Mass spectrometry (MS)-based proteomics provides deep molecular insights from patient samples, but clinical use has been limited by missing values, static biomarker panels, and the need for targeted assay development. We present a framework – Adaptive Diagnostic Architecture for Personalized Testing by Mass Spectrometry (ADAPT-MS) – that enables direct diagnostic and prognostic interpretation of discovery-mode proteomics data at the level of individual samples. ADAPT-MS dynamically retrains simple, robust classifiers based on the proteins quantified in each sample, eliminating the need for imputation or fixed panels. Applied to plasma and cerebrospinal fluid datasets across diseases and clinical centers, it achieves high performance and generalizability using robust, transparent and generalizable statistical models. A single proteomic measurement can support multiple diagnostic questions via retrospective cohort matching, with each classification taking only seconds. As population-scale proteomics datasets grow, this approach lays the foundation for scalable, real-time, and personalized diagnostics directly from proteome-wide data. Such a community effort may help to transform discovery proteomics into a routine clinical tool.
- Open Access
- 12 September 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (11) , 3174-3196
Pre-analytical drivers of bias in bead-enriched plasma proteomics
Bead-based enrichment is a promising strategy to improve depth in plasma proteomics by overcoming the dynamic range barrier. However, its robustness against pre-analytical variation has not been sufficiently characterized. Here, we systematically evaluate five plasma proteomics workflows, including three bead-based methods, a neat workflow, and a precipitation protocol using spike-ins of low-abundance proteins and defined cellular contaminants. We find that bead-based approaches enhance detection of low-abundance proteins but can be highly susceptible to systematic bias from platelet and PBMC contamination. This can inflate results by thousands of proteins, potentially explaining some of the high literature-reported numbers. A perchloric acid-based workflow shows resistance to erythrocyte and platelet-derived contamination. We investigate how centrifugation conditions, anticoagulant choice, and buffer-bead combinations modulate contamination profiles and demonstrate that bias can be mitigated by optimized sample handling. Altogether, we identify more than 13,000 different protein groups, including cellular components from the circulating proteome. Our results provide a quantitative framework for assessing workflow performance under variable sample quality and offer guidance for both biomarker discovery and quality control in clinical proteomics studies.
- 12 September 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (11) , 3174-3196
Open AccessPre-analytical drivers of bias in bead-enriched plasma proteomics
Bead-based enrichment is a promising strategy to improve depth in plasma proteomics by overcoming the dynamic range barrier. However, its robustness against pre-analytical variation has not been sufficiently characterized. Here, we systematically evaluate five plasma proteomics workflows, including three bead-based methods, a neat workflow, and a precipitation protocol using spike-ins of low-abundance proteins and defined cellular contaminants. We find that bead-based approaches enhance detection of low-abundance proteins but can be highly susceptible to systematic bias from platelet and PBMC contamination. This can inflate results by thousands of proteins, potentially explaining some of the high literature-reported numbers. A perchloric acid-based workflow shows resistance to erythrocyte and platelet-derived contamination. We investigate how centrifugation conditions, anticoagulant choice, and buffer-bead combinations modulate contamination profiles and demonstrate that bias can be mitigated by optimized sample handling. Altogether, we identify more than 13,000 different protein groups, including cellular components from the circulating proteome. Our results provide a quantitative framework for assessing workflow performance under variable sample quality and offer guidance for both biomarker discovery and quality control in clinical proteomics studies.